Invokana Tablet, Film Coated
Product Images NDC 50090-4364

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Invokana (NDC 50090-4364). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Invokana 01)

Chemical structure diagram of canagliflozin, the active ingredient in INVOKANA 300 mg oral tablets. The structure includes a glucose moiety linked to a substituted aromatic ring and a thiophene group, with a notation indicating a hemihydrate form (1/2 H2O).*

FDA Label Image

Figure 1 (Invokana 02)

A line graph depicting the least squares mean change in HbA1c (%) from baseline over 52 weeks of study. The x-axis shows study weeks from 0 to 52, including a LOCF time point, and the y-axis represents change in HbA1c percentage. Three lines represent treatments with canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride, showing HbA1c reduction trends over time.*

FDA Label Image

Figure 2 (Invokana 03)

A line chart depicting the least squares mean change in HbA1c (%) from baseline with standard error over 52 weeks. It compares canagliflozin 300 mg and sitagliptin 100 mg, illustrating the trend of effectiveness over the study period and at week 52 LOCF (last observation carried forward).*

FDA Label Image

Figure 3 (Invokana 04)

A line graph comparing the percentage of subjects with events over time (weeks) between Placebo and Cana (canagliflozin). The graph shows separate curves for Placebo (solid line) and Cana (dashed line) with lower event percentages in the Cana group. The hazard ratio (HR) with 95% confidence interval is 0.86 (0.75, 0.97). Below the x-axis, the number of subjects at various time points are listed for both groups.*

FDA Label Image

Invokana 05

A Kaplan-Meier survival curve comparing the percentage of subjects with events over time (in weeks) between canagliflozin (Cana) and placebo groups. The plot shows lower event rates in the canagliflozin group versus placebo across approximately 182 weeks. A table below the graph lists the number of subjects at risk at multiple time points for both groups.*

FDA Label Image

Label Image (Lbl500904364)

Label for INVOKANA 300 mg film-coated tablets containing canagliflozin by A-S Medication Solutions. The label specifies oral administration with 90 tablets per package. Storage instructions indicate to keep at 77 degrees Fahrenheit. The label includes NDC 50090-4364-0 and product number 6884-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.